NRx Pharmaceuticals to File Two New-Drug Applications in 2024

July 1, 2024

NRx Says New Formulation of IV Ketamine Could Be Delivered Subcutaneously

April 15, 2024

NRx Pharmaceuticals Achieves Data Lock in Phase 2B/3 Trial of NRX-101

April 10, 2024

NRx Announces Data-Sharing Agreement with Columbia University for Results from IV Ketamine Trial

December 19, 2023

NRx Pharmaceuticals Founder Jonathan Javitt Discusses Company’s Mission, Pipeline in Nasdaq Interview

December 6, 2023

NRx Pharmaceuticals Plans to Spin Off Ketamine-Focused Company

November 16, 2023